Monday, February 27, 2006
Strategic Alliance for GPCR Drug Discovery
Institute Pasteur Korea and Euroscreen Form Strategic Alliance for GPCR Drug DiscoveryThe Institute Pasteur Korea (IPK) and Euroscreen s.a. today announced a partnership to perform screening of G protein coupled receptors using internalization assays. The development at the Institute Pasteur Korea of a visual-based High Throughput Screening platform offers unique opportunities for the identification of drug candidates activating receptor internalization while Euroscreens receptor cell lines and GPCR library compounds will provide the initial direction and components for this drug discovery collaboration.
(PRWEB) February 27, 2006 -- The Institute Pasteur Korea (IPK) and Euroscreen s.a. today announced a partnership to perform screening of G protein coupled receptors using internalization assays. The development at the Institute Pasteur Korea of a visual-based High Throughput Screening platform offers unique opportunities for the identification of drug candidates activating receptor internalization while Euroscreens receptor cell lines and GPCR library compounds will provide the initial direction and components for this drug discovery collaboration.
This partnership takes thus advantage of both IPK expertise in the image analysis and HCS fields and Euroscreen competence in GPCR biology and Chemistry tools.
We are delighted to be working with Euroscreen s.a. on this GPCR Drug Discovery project. This partnership highlights the increasing interest in visual-based screening technologies to identify more selective drug candidates. It validates the screening approach we develop at IPK commented Dr. Thierry Christophe, Head of Screening Technologies and Pharmacology at Institute Pasteur Korea.
Collaborating with one of the Worlds leaders in the GPCR science sector signifies an important step in materialising IPKs innovative approach. We are enthusiastic to have found a highly competent partner in Euroscreen, to take HCS screening to the next level. added Dr. Ulf Nehrbass, Director and CEO of IPK.
This should provide our companies with a rapid, joint opportunity to develop drug candidates which selectively cause the internalization of GPCRs for their therapeutic action in vivo, said Dr. François Roman, the Head of Drug Development R&D at Euroscreen.
For further information, please contact:
Euroscreen s.a.: Tel: +32 71 348 500
Michel Detheux, Ph.D.
Head of New Target & Drug Discovery Programs Initiatives
IPK
Thierry Christophe, Ph.D.
Head of Screening Technologies and Pharmacology
Tel: 0082.2.3299.0341
Web site: www.ip-korea.org
About IP-Korea
Institute Pasteur Korea (IP-Korea) has been created in 2004 with the strategic focus on enabling technologies and therapeutics development in disease models pertaining to public health. In order to meet this goal, IP-Korea was one of the few world research centers to develop High Throughput Screening facilities based on internal and collaborative development of new screening assays. Today IP-Korea can take advantage of the diversity of its research, including biology groups, image mining, new microscopy development or medicinal and nano chemistry.
IP-Korea is a part of the International Network of Pasteur Institutes, which allows IP-Korea the access to the research developed through the 28 other Institutes. In addition, IP-Korea has agreements with the French CNRS (Centre National pour le Recherche Scientifique), the KRICT (Korea Research Institute of Chemical Technology) and the KIST (Korea Institute of Science and Technology).
In the screening area, the goal of IP-Korea is to develop disease-based assays to visualize the physiological effect of the disease on the cellular level. To this end, IP-Korea has implemented the first worldwide uHTS platform from Evotec Technologies in a BSL-3 lab including an automatized confocal microscope (Opera) but also fluorescence/luminescence readers to perform High Content and HTScreens.
For more information, please contact Dr. Philip Bernstein (email protected from spam bots)
Institute Pasteur Korea is a non-profit organization based in Seoul, South Korea.
About Euroscreen SA
Euroscreen is a world leader in G-protein coupled receptors (GPCRs). The Company integrates its research expertise in this area with its patented high-throughput AequoScreen cellular assay platform to patent new GPCR targets and drug candidates.
The Company is building its own patent portfolio of GPCR targets and novel drug leads for licensing to biopharmaceutical companies, and to date has agreements with Amersham/GE Healthcare, Cephalon, ChemDiv, Evotec, ICOS, Merck & Co, Pfizer Inc, Solvay, Syngenta and UCB. Euroscreen has also established collaborations with numerous academic centers for access to licenses to help in making available its broad menu of GPCR-based products (recombinant cell lines and membrane preparations) and services (custom screening and cloning).
Euroscreen has grown significant and strong patent positions to protect many key drug targets for licensing. Such patents include CCR5, ChemR23, GPR43, GPR7/8, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2 for type II diabetes. Euroscreen is able to offer intellectual property rights to companies for the development of therapeutic drugs that act through the above-mentioned targets. For more information regarding the Euroscreens portfolio, please contact Dr. Vincent Lannoy.
Euroscreen is a privately held company based in Brussels, Belgium with 80 employees of which 50 are in R&D.
# # #
Press Contact: Alfred Gray
Company Name: EUROSCREEN
Email: email protected from spam bots
Phone: 716 308 6693
Website: www.euroscreen.com_______________________________________________________
Free trade and professional industry magazines are available at
http://www.consultant-directory.tradepub.com
_______________________________________________________
Lung Cancer caused by asbestos exposure is known as
Mesothelioma. Learn more about this killer cancer.
Visit http://www.Mesothelioma-Search-Engine.com
_______________________________________________________
JR Roberts, a Security Expert Witness can help you prosecute or defend
your criminal or negligent liability case in court.
http://www.jrrobertssecurity.com/expert.html
__________________________________________________
http://www.legal-search-engine.com
http://www.vioxx-search-engine.com
http://www.security-guard.org
__________________________________________________
